Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392232 · ClinicalTrials.gov registry record · Phase 2
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
A Phase 2 study of COVID-19 and Coronavirus, sponsored by TriHealth.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 2
- Study locations
NCT04392232: Completed Phase 2 study of COVID-19 and Coronavirus, sponsored by TriHealth.
NCT04392232 is a Phase 2 study of COVID-19 and Coronavirus that has completed, run by TriHealth. The registered enrollment target is 159 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04392232, a Phase 2 study of COVID-19 and Coronavirus, has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 2
- Study locations
Study Summary
Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.
Primary Outcome
% patients who survived
Conditions Studied
Interventions
- DRUG Convalescent Plasma
Study Locations (2)
Ohio
- Good Samaritan Hospital - Cincinnati
- Bethesda North Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
What the finished NCT04392232 record still lists
NCT04392232 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04392232 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04392232 about?
NCT04392232 is a clinical study titled "A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection". Purpose of Study • The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.
What is the current status of trial NCT04392232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2020-05-05. Estimated completion is 2021-09-21.
What conditions does trial NCT04392232 study?
This clinical trial studies the following conditions: COVID-19, Coronavirus, Convalescent Plasma.
What interventions are being tested in trial NCT04392232?
The interventions under investigation include: Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04392232?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04392232 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04392232's enrollment target sits among peer trials
159 170th of 298 higher than 129 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI